Paper42581900
Precision oncology in the treatment of patients with bone sarcomas: an up-to-date narrative review.
Yarar S and 1 other. Explor Target Antitumor Ther, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Precision oncology in the treatment of patients with bone sarcomas: an up-to-date narrative review. Papers, record 42581900. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42581900
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Precision oncology in the treatment of patients with bone sarcomas: an up-to-date narrative review.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References132
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 41037832 | HDAC inhibitor (SAHA) enhances B7-H3-specific CAR T cell cytotoxic efficacy against chondrosarcoma cells and prolongs survival in an orthotopic mouse model. | Transl Oncol | 2025 | https://conductscience.org/library/papers/41037832 | PubMed |
| 2 | 40422235 | Modeling Tumor Microenvironment Complexity In Vitro: Spheroids as Physiologically Relevant Tumor Models and Strategies for Their Analysis. | Cells | 2025 | https://conductscience.org/library/papers/40422235 | PubMed |
| 3 | 28133974 | Novel therapeutic approaches in chondrosarcoma. | Future Oncol | 2017 | https://conductscience.org/library/papers/28133974 | PubMed |
| 4 | 28707624 | Three-dimensional (3D) culture in sarcoma research and the clinical significance. | Biofabrication | 2017 | https://conductscience.org/library/papers/28707624 | PubMed |
| 5 | 30006631 | Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. | Sci Rep | 2018 | https://conductscience.org/library/papers/30006631 | PubMed |
| 6 | 26962160 | Chemotherapy for Bone Sarcoma in Adults. | J Oncol Pract | 2016 | https://conductscience.org/library/papers/26962160 | PubMed |
| 7 | 34535153 | The basic characteristics of extracellular vesicles and their potential application in bone sarcomas. | J Nanobiotechnology | 2021 | https://conductscience.org/library/papers/34535153 | PubMed |
| 8 | 26304877 | Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/26304877 | PubMed |
| 9 | 39622151 | Patient-derived tumor organoids: A preclinical platform for personalized cancer therapy. | Transl Oncol | 2025 | https://conductscience.org/library/papers/39622151 | PubMed |
| 10 | 32483734 | Using Liquid Biopsy in the Treatment of Patient with OS. | Adv Exp Med Biol | 2020 | https://conductscience.org/library/papers/32483734 | PubMed |
| 11 | 34938658 | Metabolic Pathways and Targets in Chondrosarcoma. | Front Oncol | 2021 | https://conductscience.org/library/papers/34938658 | PubMed |
| 12 | 27447864 | Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics. | Oncotarget | 2017 | https://conductscience.org/library/papers/27447864 | PubMed |
| 13 | 40426987 | Biomarker-Driven Approaches to Bone Metastases: From Molecular Mechanisms to Clinical Applications. | Biomedicines | 2025 | https://conductscience.org/library/papers/40426987 | PubMed |
| 14 | 36046479 | Clinical implementation of plasma cell-free circulating tumor DNA quantification by digital droplet PCR for the monitoring of Ewing sarcoma in children and adolescents. | Front Pediatr | 2022 | https://conductscience.org/library/papers/36046479 | PubMed |
| 15 | 33894338 | Osteosarcoma, chondrosarcoma and Ewing sarcoma: Clinical aspects, biomarker discovery and liquid biopsy. | Crit Rev Oncol Hematol | 2021 | https://conductscience.org/library/papers/33894338 | PubMed |
| 16 | 35746359 | A Smarter Health through the Internet of Surgical Things. | Sensors (Basel) | 2022 | https://conductscience.org/library/papers/35746359 | PubMed |
| 17 | 32078813 | Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. | Lancet Oncol | 2020 | https://conductscience.org/library/papers/32078813 | PubMed |
| 18 | 37174021 | Molecular In-Depth Characterization of Chondrosarcoma for Current and Future Targeted Therapies. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37174021 | PubMed |
| 19 | 31970591 | Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies. | Cancer Metastasis Rev | 2019 | https://conductscience.org/library/papers/31970591 | PubMed |
| 20 | 41749815 | From Bench to Bedside: Advancements in Precision Oncology and Drug Discovery for Osteosarcoma. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41749815 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42581900
GET https://conductscience.org/api/papers/v1/42581900/references?page=2